Baker BROS. Advisors LP Purchases 677,966 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Baker BROS. Advisors LP raised its holdings in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 123.4% in the 3rd quarter, Holdings Channel.com reports. The fund owned 1,227,178 shares of the company’s stock after buying an additional 677,966 shares during the period. Baker BROS. Advisors LP’s holdings in Centessa Pharmaceuticals were worth $19,623,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in CNTA. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Centessa Pharmaceuticals by 47.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC lifted its position in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP boosted its stake in shares of Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after buying an additional 3,108 shares during the last quarter. Sandia Investment Management LP bought a new position in shares of Centessa Pharmaceuticals in the 2nd quarter valued at about $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter valued at about $99,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Centessa Pharmaceuticals Stock Up 1.8 %

CNTA stock opened at $17.91 on Monday. Centessa Pharmaceuticals plc has a 1-year low of $5.58 and a 1-year high of $18.74. The business’s 50 day simple moving average is $16.22 and its 200 day simple moving average is $12.69. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The firm has a market capitalization of $2.36 billion, a PE ratio of -11.71 and a beta of 1.47.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.05. As a group, research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Insider Buying and Selling

In other news, CEO Saurabh Saha sold 175,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $16.52, for a total value of $2,891,000.00. Following the transaction, the chief executive officer now owns 776,924 shares of the company’s stock, valued at approximately $12,834,784.48. This represents a 18.38 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Gregory M. Weinhoff sold 25,000 shares of Centessa Pharmaceuticals stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $15.00, for a total value of $375,000.00. Following the sale, the insider now directly owns 223,369 shares of the company’s stock, valued at approximately $3,350,535. The trade was a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 375,128 shares of company stock valued at $6,148,522. Company insiders own 11.59% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently commented on CNTA shares. Guggenheim increased their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a research report on Friday, November 15th. B. Riley assumed coverage on Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price objective for the company. Oppenheimer restated an “outperform” rating and set a $14.00 target price on shares of Centessa Pharmaceuticals in a report on Wednesday, August 14th. Jefferies Financial Group upped their price target on shares of Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, September 11th. Finally, BMO Capital Markets lifted their price objective on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and an average target price of $25.83.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.